glp-1 usage statistics Products - Data Briefs - Number 537 GLP-1 Survey: 37.5% of People

Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review

One blocks opioid receptors tied to alcohols reward

HealthVerity enables pharmaceutical manufacturers to go beyond traditional claims analysis by delivering verified, linked insights into how GLP-1 drugs are being used across populations

Animal studies show promising results for reversing signs of aging at the molecular and functional levels

Additionally, some patients may qualify for clinical trials, which can provide access to new medications at reduced or no cost

Many patients plateau at 10 mg or stop escalating due to side effects, never reaching their personal therapeutic dose